[Federal Register Volume 80, Number 154 (Tuesday, August 11, 2015)]
[Notices]
[Pages 48105-48107]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2015-19659]
=======================================================================
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Agency for Healthcare Research and Quality
Scientific Information Request on Omega 3 Fatty Acids and
Cardiovascular Disease--Update
AGENCY: Agency for Healthcare Research and Quality (AHRQ), HHS.
ACTION: Request for Scientific Information Submissions.
-----------------------------------------------------------------------
SUMMARY: The Agency for Healthcare Research and Quality (AHRQ) is
seeking scientific information submissions from the public. Scientific
information is being solicited to inform our review of Omega 3 Fatty
Acids and Cardiovascular Disease--Update, which is currently being
conducted by the AHRQ's Evidence-based Practice Centers (EPC) Programs.
Access to published and unpublished pertinent scientific information
will improve the quality of this review. AHRQ is conducting this
systematic review pursuant to Section 902(a) of the Public Health
Service Act, 42 U.S.C. 299a(a).
DATES: Submission Deadline on or before September 10, 2015.
ADDRESSES: Online submissions: http://effectivehealthcare.AHRQ.gov/index.cfm/submit-scientific-information-packets/. Please select the
study for which you are submitting information from the list to upload
your documents.
Email submissions: src.org">SIPS@epc-src.org. Print submissions: Mailing
Address: Portland VA Research Foundation, Scientific Resource Center,
ATTN:
[[Page 48106]]
Scientific Information Packet Coordinator, PO Box 69539, Portland, OR
97239.
Shipping Address (FedEx, UPS, etc.): Portland VA Research Foundation,
Scientific Resource Center, ATTN: Scientific Information Packet
Coordinator, 3710 SW U.S. Veterans Hospital Road, Mail Code: R&D 71,
Portland, OR 97239.
FOR FURTHER INFORMATION CONTACT: Ryan McKenna, Telephone: 503-220-8262
ext. 58653 or Email: src.org">SIPS@epc-src.org.
SUPPLEMENTARY INFORMATION: The Agency for Healthcare Research and
Quality has commissioned the Evidence-based Practice Centers (EPC)
Programs to complete a review of the evidence for Omega 3 Fatty Acids
and Cardiovascular Disease--Update.
The EPC Program is dedicated to identifying as many studies as
possible that are relevant to the questions for each of its reviews. In
order to do so, we are supplementing the usual manual and electronic
database searches of the literature by requesting information from the
public (e.g., details of studies conducted). We are looking for studies
that report on Omega 3 Fatty Acids and Cardiovascular Disease--Update,
including those that describe adverse events. The entire research
protocol, including the key questions, is also available online at:
http://effectivehealthcare.AHRQ.gov/search-for-guides-reviews-and-reports/?pageaction=displayproduct&productID=2060.
This notice is to notify the public that the EPC Program would find
the following information on Omega 3 Fatty Acids and Cardiovascular
Disease--Update helpful:
[ssquf] A list of completed studies that your organization has
sponsored for this indication. In the list, please indicate whether
results are available on ClinicalTrials.gov along with the
ClinicalTrials.gov trial number.
[ssquf] For completed studies that do not have results on
ClinicalTrials.gov, please provide a summary, including the following
elements: study number, study period, design, methodology, indication
and diagnosis, proper use instructions, inclusion and exclusion
criteria, primary and secondary outcomes, baseline characteristics,
number of patients screened/eligible/enrolled/lost to follow-up/
withdrawn/analyzed, effectiveness/efficacy, and safety results.
[ssquf] A list of ongoing studies that your organization has
sponsored for this indication. In the list, please provide the
ClinicalTrials.gov trial number or, if the trial is not registered, the
protocol for the study including a study number, the study period,
design, methodology, indication and diagnosis, proper use instructions,
inclusion and exclusion criteria, and primary and secondary outcomes.
[ssquf] Description of whether the above studies constitute all
Phase II and above clinical trials sponsored by your organization for
this indication and an index outlining the relevant information in each
submitted file.
Your contribution will be very beneficial to the EPC Program. The
contents of all submissions will be made available to the public upon
request. Materials submitted must be publicly available or can be made
public. Materials that are considered confidential; marketing
materials; study types not included in the review; or information on
indications not included in the review cannot be used by the EPC
Program. This is a voluntary request for information, and all costs for
complying with this request must be borne by the submitter.
The draft of this review will be posted on AHRQ's EPC Program Web
site and available for public comment for a period of 4 weeks. If you
would like to be notified when the draft is posted, please sign up for
the email list at: http://effectivehealthcare.AHRQ.gov/index.cfm/join-the-email-list1/.
The systematic review will answer the following questions. This
information is provided as background. AHRQ is not requesting that the
public provide answers to these questions. The entire research
protocol, is available online at: http://effectivehealthcare.AHRQ.gov/search-for-guides-reviews-and-reports/?pageaction=displayproduct&productID=2060.
The Key Questions
1. What is the efficacy or association of n-3 Fatty Acids (FA)
(eicosapentaenoic acid [EPA], docosahexaenoic acid [DHA]EPA+DHA,
docosapentaenoic acid [DPA], stearidonic acid [SDA], alpha-linolenic
acid [ALA], or total n-3 Fatty Acids) exposures in reducing
cardiovascular disease (CVD) outcomes (incident CVD events including
all-cause mortality, CVD mortality, non-fatal CVD events, new diagnosis
of CVD, peripheral vascular disease, congestive heart failure, major
arrhythmias, and hypertension diagnosis) and specific CVD risk factors
(blood pressure, key plasma lipids)?
[cir] What is the efficacy or association of n-3 FA in preventing
CVD outcomes in people
[ssquf] Without known CVD (primary prevention)
[ssquf] At high risk for CVD (primary prevention)
[ssquf] With known CVD (secondary prevention)?
[cir] What is the relative efficacy of different n-3 FAs on CVD
outcomes and risk factors?
[cir] Can the CVD outcomes be ordered by strength of intervention
effect of n-3 FAs?
2. n-3 FA variables and modifiers:
[cir] How does the efficacy or association of n-3 FA in preventing
CVD outcomes and with CVD risk factors differ in subpopulations,
including men, premenopausal women, postmenopausal women, and different
age or race/ethnicity groups?
[cir] What are the effects of potential confounders or interacting
factors--such as plasma lipids, body mass index, blood pressure,
diabetes, kidney disease, other nutrients or supplements, and drugs
(e.g., statins, aspirin, diabetes drugs, hormone replacement therapy)?
[cir] What is the efficacy or association of different ratios of n-
3 FA components in dietary supplements or biomarkers, on CVD outcomes
and risk factors?
[cir] How does the efficacy or association of n-3 FA on CVD
outcomes and risk factors differ by ratios of different n-3 FAs--DHA,
EPA, and ALA, or other n-3 FAs?
[cir] How does the efficacy or association of n-3 FA on CVD
outcomes and risk factors differ by source (e.g., fish and seafood,
common plant oils (e.g., soybean, canola), fish oil supplements,
fungal-algal supplements, flaxseed oil supplements)?
[cir] How does the ratio of n-6 FA to n-3 FA intakes or biomarker
concentrations affect the efficacy or association of n-3 FA on CVD
outcomes and risk factors?
[cir] Is there a threshold or dose-response relationship between n-
3 FA exposures and CVD outcomes and risk factors? Does the study type
affect these relationships?
[cir] How does the duration of intervention or exposure influence
the effect of n-3 FA on CVD outcomes and risk factors?
[cir] What is the effect of baseline n-3 FA status (intake or
biomarkers) on the efficacy of n-3 FA intake or supplementation on CVD
outcomes and risk factors?
3. Adverse events:
[cir] What adverse effects are related to n-3 FA intake or
biomarker concentrations (in studies of CVD outcomes and risk factors)?
[cir] What adverse events are reported specifically among people
with CVD or
[[Page 48107]]
diabetes (in studies of CVD outcomes and risk factors)?
PICOTS (Population, Intervention, Comparator, Outcome, Timing, Setting)
Populations
Healthy adults (>=18 yr) without CVD or with low to
intermediate risk for CVD
Adults at high risk for CVD (e.g., with diabetes,
cardiometabolic syndrome, hypertension, dyslipidemia, non-dialysis
chronic kidney disease)
Adults with clinical CVD (e.g., history of myocardial
infarction, angina, transient ischemic attacks)
Exclude populations chosen for having a non-CVD or non-
diabetes-related disease (e.g., cancer, gastrointestinal disease,
rheumatic disease, dialysis)
Interventions/Exposures
n-3 FA supplements
n-3 FA supplemented foods (e.g., eggs)
n-3 FA content in diet (e.g., from food frequency
questionnaires)
Biomarkers of n-3 FA intake
n-3 content of food or supplements must be quantified (e.g.,
exclude fish diet studies where only servings/week defined,
Mediterranean diet studies without n-3 quantified). n-3 quantification
can be of total n-3 FA, of a specific n-3 FA (e.g., ALA) or of combined
EPA+DHA (``marine oil'').
Exclude n-3 FA dose >=6 g/day (except for adverse events)
Exclude weight loss interventions
Comparators
Placebo or no n-3 FA intervention
Different n-3 FA source intervention
Different n-3 FA concentration intervention
Different n-3 FA dietary exposure (e.g., comparison of
quantiles)
Different n-3 FA biomarker levels (e.g., comparison of
quantiles)
Outcomes
All-cause mortality
Cardiovascular, cerebrovascular, and peripheral vascular
events:
[cir] Fatal vascular events (e.g., due to myocardial infarction,
stroke)
[cir] Non-fatal vascular events (e.g., myocardial infarction, stroke/
cardiovascular accident, transient ischemic attack, unstable angina)
[cir] Coronary heart disease, new diagnosis
[cir] Congestive heart failure, new diagnosis
[cir] Cerebrovascular disease, new diagnosis
[cir] Peripheral vascular disease, new diagnosis
[cir] Ventricular arrhythmia, new diagnosis
[cir] Supraventricular arrhythmia, new diagnosis
[cir] Major vascular interventions/procedures (e.g, revascularization,
thrombolysis, lower extremity amputation, defibrillator placement)
Major CVD risk factors (intermediate outcomes):
[cir] Blood pressure (new-onset hypertension, systolic, diastolic, and
mean arterial pressure)
[cir] Key plasma lipids (i.e., high density lipoprotein cholesterol
[HDL-c], low density lipoprotein cholesterol [LDL-c], total/HDL-c
ratio, LDL-c/HDL-c ratio, triglycerides)
Adverse events (e.g., bleeding, major gastrointestinal
disturbance), only from intervention studies of supplements
Timing
Clinical outcomes, including new-onset hypertension (all study
designs): >=1 year followup (and intervention duration, as applicable)
Intermediate outcomes (blood pressure and plasma lipids) (all
study designs): >=1 month followup
Adverse events (all study designs): No minimum followup
Setting
Community-Dwelling (Non-Institutionalized) Individuals Study Design
Randomized Controlled Trials (RCTs) (all outcomes)
Randomized cross-over studies (blood pressure and plasma
lipids, adverse events), minimum washout period to be determined
Prospective nonrandomized comparative studies (clinical
outcomes, adverse events)
Prospective cohort (single group) studies, where groups are
compared based on n-3 FA intake or intake biomarker values (clinical
outcomes)
Exclude: Retrospective or case control studies or cross-
sectional studies (but include prospective nested case control
studies). Studies must have measure of intake prior to outcome.
Minimum sample sizes (All outcomes: To be determined)
English language publications
Sharon B. Arnold,
Deputy Director.
[FR Doc. 2015-19659 Filed 8-10-15; 8:45 am]
BILLING CODE 4160-90-P